PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31313024-8	2019	Further, LV-antagomiR-7-induced osteoblast cytoprotection against Dex was abolished by the EGFR inhibitors AG1478 and PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	118-126	epidermal growth factor receptor	Mus musculus	91-95	
26464147-7	2016	BALB/c mice were intratracheally instilled with the EGFR kinase inhibitor PD153035 2 h prior to O3 exposure and every other day thereafter.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	epidermal growth factor receptor	Mus musculus	52-56	
30735525-5	2019	Here, we investigated whether inhibiting EGFR using the EGFR tyrosine kinase inhibitor (TKI) PD153035 improves NAFLD.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	93-101	epidermal growth factor receptor	Mus musculus	41-45	
30735525-7	2019	Inhibiting EGFR using PD153035 significantly reduced phosphatidylinositol-3-kinase/protein kinase B signaling and sterol responsive elementary binding protein 1 and 2 expression, which prevented HFD-induced hepatic steatosis and hypercholesterolemia by reducing de novo lipogenesis and cholesterol synthesis and enhancing fatty acid oxidation.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	22-30	epidermal growth factor receptor	Mus musculus	11-15	
27436370-7	2017	PD153035 (EGFR inhibitor) and U0126 (ERK inhibitor) inhibited AQP3 expression and also the attachment and outgrowth of blastocysts.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	0-8	epidermal growth factor receptor	Mus musculus	10-14	
26464147-12	2016	Administration of PD153035 resulted in a significantly reduced lung inflammation as well as EGFR phosphorylation induced by O3 exposure.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	18-26	epidermal growth factor receptor	Mus musculus	92-96	
19696185-0	2009	EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	32-40	epidermal growth factor receptor	Mus musculus	0-4	
22694592-9	2012	EGFR inhibitor PD153035 suppressed regeneration of 50% grafts and largely abrogated stimulation of regeneration of 30% grafts by AR.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	15-23	epidermal growth factor receptor	Mus musculus	0-4	
21058048-1	2011	OBJECTIVE: A radioiodinated analog of PD153035 (m-IPQ) was evaluated as a potential epidermal growth factor receptor tyrosine kinase (EGFR-TK) activity imaging ligand for SPECT.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	38-46	epidermal growth factor receptor	Mus musculus	134-138	
21058048-11	2011	The selectivity toward EGFR-TK of m-IPQ was confirmed by the pretreatment experiment with EGFR-TK specific inhibitors, PD153035, Genistein.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	119-127	epidermal growth factor receptor	Mus musculus	23-27	
19696185-4	2009	We investigated, herein, in vivo efficacy and associated molecular mechanisms by which PD153035, an EGFR tyrosine kinase inhibitor, improved diabetes control and insulin action.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	87-95	epidermal growth factor receptor	Mus musculus	100-104	
12466022-4	2003	Pharmacological inhibition of EGF receptor kinase activity with AG1478 or PD153035 blocked urea-inducible transcription and expression of the immediate-early gene, Egr-1.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	74-82	epidermal growth factor receptor	Mus musculus	30-42	
9774435-5	1998	This MAPK stimulatory activity could be specifically blocked by the epidermal growth factor receptor (EGFR) inhibitors, PD153035 and PD158780.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	120-128	epidermal growth factor receptor	Mus musculus	102-106	
18398842-5	2008	These cellular responses were blocked by inhibiting the tyrosine kinase activity of EGFR with PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	94-102	epidermal growth factor receptor	Mus musculus	84-88	
18171992-9	2007	Activation of the epidermal growth factor receptor (EGFR) seemed to underlie the ability of TPA to activate Akt as both PD153035, an inhibitor of EGFR, and GW2974, a dual-specific inhibitor of both EGFR and erbB2, were able to effectively reduce TPA-induced Akt phosphorylation as well as TPA-stimulated EGFR and erbB2 tyrosine phosphorylation in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	120-128	epidermal growth factor receptor	Mus musculus	18-50	
18171992-9	2007	Activation of the epidermal growth factor receptor (EGFR) seemed to underlie the ability of TPA to activate Akt as both PD153035, an inhibitor of EGFR, and GW2974, a dual-specific inhibitor of both EGFR and erbB2, were able to effectively reduce TPA-induced Akt phosphorylation as well as TPA-stimulated EGFR and erbB2 tyrosine phosphorylation in a dose-dependent manner.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	120-128	epidermal growth factor receptor	Mus musculus	52-56	
17636266-7	2007	Coculture with bone metastatic breast cancer MDA-MB-231 cells had similar effects on the expression of OPG and MCP1 in the osteoblastic cells, and those effects could be partially abolished by the EGFR inhibitor PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	212-220	epidermal growth factor receptor	Mus musculus	197-201	
15557365-6	2004	Pretreatment with the EGFR inhibitors AG1478 (5 micromol/L) or PD153035 (1 micromol/L) significantly decreased MT.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	63-71	epidermal growth factor receptor	Mus musculus	22-26